Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Financial Results

Every financial results filing by a US-listed company that our alert engine sent, newest first.

4:26 PM ET 8-K
Financial Results Nektar Therapeutics NKTR

Nektar Therapeutics Financial Results

Nektar Therapeutics reported third quarter 2026 financial results, highlighting a cash position of $952.9 million and the initiation of Phase 3 registrational trials for rezpegaldesleukin in atopic dermatitis. The company reported a net loss of $55.7 million on revenue of $9.4 million, with R&D expenses increasing to support its late-stage clinical programs.

Term
Q3 2026

“This was a pivotal quarter for Nektar as we moved rezpegaldesleukin quickly into Phase 3 development. We have now initiated all three global ZENITH AD registrational trials in atopic dermatitis and our global ZENITH AA registrational trial in alopecia areata is on track to begin in December, earlier than previously planned.”

Howard Robin, President and Chief Executive Officer of Nektar
4:25 PM ET 10-Q
Financial Results Innovate Corp. VATE

Innovate Q3 2026 Results: Turns Profitable, Net Income $26.5M

INNOVATE Corp. reported a significant turnaround for the third quarter of 2026, with net income attributable to common stockholders of $15.8 million compared to a net loss of $9.4 million in the prior year. Revenue grew to $495.5 million for the quarter, driven by operations and a $32.9 million gain on the sale of a controlling interest in a subsidiary.

Key figure
Net income $26.5M
4:24 PM ET 8-K
Financial Results Armata Pharmaceuticals, Inc. ARMP

Armata Pharmaceuticals Financial Results

Armata Pharmaceuticals reported its third quarter 2026 financial results and provided an update on its AP-SA02 Phase 3 program. The company is finalizing study designs with the FDA and has completed engineering runs at its cGMP manufacturing facility to support the upcoming pivotal trial.

“We continue to advance toward our most important near-term objective: initiating the Phase 3 superiority study of AP-SA02. We have progressed from planning to establishing the operational infrastructure needed to execute a large, pivotal clinical study.”

Dr. Deborah Birx, Chief Executive Officer

“We believe the FDA’s recent Breakthrough Therapy designation further underscores AP-SA02’s clinical potential. We also appreciate the continued financial support of the U.S. Department of War (“DoW”), which comes at an important time as we prepare for this next critical stage of clinical development.”

Dr. Deborah Birx, Chief Executive Officer
4:24 PM ET 10-Q
Financial Results Innventure, Inc. INV

Innventure Q3 2026 Results: Net Loss of $202M, Loss Widens

Innventure, Inc. reported a significant net loss for the nine months ended September 30, 2026, primarily driven by a $323.5 million goodwill impairment charge. While revenue increased to $3.88 million from $1.23 million year-over-year, the company faces substantial liquidity risks and is exploring strategic alternatives for its subsidiaries AeroFlexx and Refinity.

Key figure
Net loss $202M
4:24 PM ET 8-K
Financial Results FGI Industries Ltd. FGI

FGI Industries Financial Results

FGI Industries reported third quarter 2026 revenue of $31.7 million, an 11.6% year-over-year decline driven by softness in housing and remodeling activity. Despite the revenue drop, gross margin expanded by 110 basis points to 27.6% due to cost discipline and product mix management, though the company recorded a net loss of $0.9 million.

“FGI reported total revenue of $31.7 million in the quarter, representing a year-over-year decline of 11.6%. The quarter reflected a challenging market environment, with continued softness in housing and remodeling activity, reduced customer purchasing and delayed projects weighing on demand across several product categories.”

Dave Bruce, CEO of FGI

“Revenue declined 11.6% year-over-year in the third quarter, reflecting softness in our core North American sanitaryware and shower system categories. Operating expenses remained disciplined, declining on a year-to-date basis, and we continued to advance our commercial pipeline and strengthen sales reporting and account-level performance tracking.”

Jae Chung, Chief Financial Officer of FGI
4:24 PM ET 8-K
Financial Results Xos, Inc. XOS

Xos Financial Results

Xos, Inc. reported its third quarter 2026 financial results, achieving its third consecutive quarter of positive GAAP gross profit and a 17% sequential revenue increase to $5.5 million. Despite a year-over-year revenue decline, the company improved its nine-month GAAP gross margin to 26.9% and reduced operating expenses by 10% through disciplined cost management.

Term
Q3 2026
4:24 PM ET 10-Q
Financial Results Codexis, Inc. CDXS ▶ Call

Codexis Q3 2026 Results: Net Loss of $8.13M, Loss Narrows

Codexis reported a significant increase in total revenues to $19.26 million for Q3 2026, up from $8.60 million in the prior year, driven primarily by product revenue growth. The company successfully reduced its quarterly net loss to $8.13 million compared to $19.62 million in Q3 2025, while strengthening its cash position through a $24.9 million net equity offering.

Key figure
Net loss $8.13M
4:23 PM ET 10-Q
Financial Results Star Equity Holdings, Inc. STRR

Star Equity Holdings Q3 2026 Results: Net Loss of $1.59M, Loss Narrows

Star Equity Holdings, Inc. reported a net loss of $1.59 million for the third quarter of 2026, compared to a $1.76 million loss in the prior year period, despite a 12.4% increase in total revenues to $53.9 million. The company's year-to-date net loss widened significantly to $7.23 million as operating expenses rose, particularly in salaries and general office costs.

Key figure
Net loss $1.59M
4:23 PM ET 10-Q
Financial Results Scribe Therapeutics, Inc. SCTX

Scribe Therapeutics Q3 2026 Results: Net Loss of $9.86M

Scribe Therapeutics reported a net loss of $33.0 million for the nine months ended September 30, 2026, compared to a $12.6 million loss in the prior year period, primarily due to a significant decrease in collaboration revenue. During the quarter, the company completed its initial public offering and concurrent private placement, resulting in a cash and cash equivalents balance of $172.1 million.

Key figure
Net loss $9.86M
4:23 PM ET 10-Q
Financial Results Adams Street Credit Solutions Fund

Adams Street Credit Solutions Fund Q3 2026 Results: Net Income $1.13M, Up 183.2% YoY

Adams Street Credit Solutions Fund (ASCEND) is a business development company that reported 3,326,403.646 Class I shares outstanding as of November 12, 2026. The filing indicates the fund is an emerging growth company and a non-accelerated filer, focusing on middle-market senior loans and secured debt investments.

Key figure
Net income $1.13M · +183.2% YoY
4:23 PM ET 10-K
Financial Results Rmr Group Inc. RMR ▶ Call

Rmr Group FY 2026 Results: Net Income $10.7M, Down 39.2% YoY

For the fiscal year ended September 30, 2026, RMR Group Inc. reported total revenues of $643.2 million, an 8.2% decrease from the prior year, primarily driven by lower reimbursable costs. Net income attributable to the company fell 39.2% to $10.7 million, impacted by a $19.1 million impairment loss and increased interest expenses related to new property acquisitions.

Key figure
Net income $10.7M · -39.2% YoY
4:22 PM ET 10-Q
Financial Results Avidbank Holdings, Inc. AVBH

Avidbank Holdings Q3 2026 Results: Turns Profitable, Net Income $10.2M

Avidbank Holdings reported a significant regulatory shift as of September 30, 2026, with none of its reciprocal deposits classified as brokered deposits due to the 21st Century ROAD to Housing Act. This compares to $475.4 million in brokered deposits at year-end 2025. The company also recorded $1.3 million in bank-owned life insurance death benefits during the first nine months of 2026.

Key figure
Net income $10.2M
4:22 PM ET 10-Q
Financial Results Solv Energy, Inc. MWH ▶ Call

Solv Energy Q3 2026 Results: Net Income $69.9M, Down 0.3% YoY

SOLV Energy, Inc. is a non-accelerated filer reporting for the quarter ended September 30, 2026. The filing highlights risks related to project timing, labor costs, and material availability, while noting that the company has identified material weaknesses in its internal control over financial reporting.

Key figure
Net income $69.9M · -0.3% YoY
4:22 PM ET 10-Q
Financial Results Principal Credit Real Estate Income Trust

Principal Credit Real Estate Income Trust Q3 2026 Results: Net Income $3.09M, Up 13.7% YoY

Principal Credit Real Estate Income Trust reported net income of $6.93 million for the nine months ended September 30, 2026, a significant increase from $2.15 million in the prior year period. Total assets grew to $494.7 million, driven by investments in loans receivable, while the company continued to issue multiple classes of common shares to fund its real estate credit activities.

Key figure
Net income $3.09M · +13.7% YoY
4:22 PM ET 8-K
Financial Results Ensysce Biosciences, Inc. ENSC

Ensysce Biosciences Financial Results

Ensysce Biosciences reported financial results for the third quarter of 2026, highlighting the completion of its acquisition of Cy Biopharma and the addition of lead asset CY200 for Complex Regional Pain Syndrome. The company ended the quarter with a strengthened cash position of $29.7 million and submitted a Phase 2a protocol for CY200 to the UK's MHRA.

Term
Q3 2026

“Ensysce is a fundamentally different company today than it was at the start of the year. With CY200, we now lead with a potentially first-in-class approach to CRPS, a devastating condition for which there is currently no FDA-approved therapy.”

Dr. Lynn Kirkpatrick, Chief Executive Officer

“Our priority since the acquisition has been to advance CY200 efficiently, and submitting the CYBIO 001 protocol to the MHRA in September was a significant first step.”

James Morrison, President of Ensysce
4:22 PM ET 8-K
Financial Results Innventure, Inc. INV

Innventure Financial Results

Innventure, Inc. reported third quarter 2026 financial results, highlighting a strategic transformation to reduce parent-level costs and focus resources on its interest in Accelsius. The company reduced its headcount from 40 to 15 since Q1 and is evaluating strategic alternatives for its AeroFlexx and Refinity businesses to address near-term liquidity needs.

Term
3 months

“Over the last few months, our management team and Board have taken decisive steps to transform Innventure into a leaner, more focused organization, concentrating our resources on the opportunities we believe offer the clearest path to driving shareholder value.”

Bill Grieco, Chief Executive Officer of Innventure

“These actions share the common objective to preserve and maximize the value of our interest in Accelsius while giving the business the necessary resources to realize its full potential.”

Bill Grieco, Chief Executive Officer of Innventure
4:22 PM ET 10-Q
Financial Results Crown Crafts Inc CRWS

Crown Crafts Q2 2026 Results: Net Income $1.32M, Up 13.8% YoY

Crown Crafts Inc. reported net income of $1.3 million for the quarter ended September 27, 2026, compared to $1.2 million in the prior year period, despite a decrease in net sales from $23.7 million to $19.0 million. For the six-month period, net income significantly improved to $3.4 million from $53,000, driven by a substantial reduction in the cost of products sold and improved gross profit margins.

Key figure
Net income $1.32M · +13.8% YoY
4:22 PM ET 10-Q
Financial Results Jefferson Capital, Inc. JCAP

Jefferson Capital Q3 2026 Results: Net Income $46.9M, Up 22.1% YoY

Jefferson Capital, Inc. reported total revenues of $539.5 million for the nine months ended September 30, 2026, an increase from $458.5 million in the prior year period, primarily driven by higher portfolio income. Total assets grew to $2.26 billion as of September 30, 2026, while stockholders' equity increased to $518.1 million.

Key figure
Net income $46.9M · +22.1% YoY
4:22 PM ET 10-Q
Financial Results Anaptysbio, Inc ANAB

Anaptysbio Q1 2026 Results: Net Income $3.88M, Down 74.4% YoY

AnaptysBio reported net income of $3.9 million for the quarter ended September 30, 2026, compared to $15.1 million in the prior year period. The company's financial structure has shifted significantly following the spin-off of its Biopharma segment, which is now presented as discontinued operations.

Key figure
Net income $3.88M · -74.4% YoY
4:22 PM ET 8-K
Financial Results Cardiff Oncology, Inc. CRDF

Cardiff Oncology Financial Results

Cardiff Oncology reported Q3 2026 financial results and provided a clinical update on its Phase 2 trial of onvansertib in first-line RAS-mutated mCRC, noting that median PFS has not yet been reached in the 30 mg arm. The company is preparing for a registrational Phase 3 trial expected to start in Q1 2027 and reported a cash position of $68.1 million as of September 30, 2026.

Term
Q3 2026

“We’re greatly encouraged by the performance of onvansertib in first-line RAS-mutated mCRC. As the data mature, the benefit of onvansertib in combination with FOLFIRI/bev is becoming more evident, with growing separation between the onvansertib and control arms.”

Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology

“Building on the strength of these data, we are actively preparing for our upcoming registrational trial. There are currently no treatment options specifically approved for patients with pan RAS-mutated mCRC in the first-line setting and we believe onvansertib has the potential to become an important new treatment for these patients.”

Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology
4:22 PM ET 8-K
Financial Results Innovate Corp. VATE

Innovate Financial Results

INNOVATE Corp. reported its third quarter 2026 financial results, highlighted by a 42.8% increase in revenue to $495.5 million and a return to profitability with net income of $15.8 million. During the period, the company executed major strategic divestitures, including the sale of a controlling interest in HC2 Broadcasting and the completion of the DBM Global sale to IES Holdings shortly after quarter-end.

Term
Q3 2026

“DBM Global capped its final quarter under our ownership with exceptional performance, and we took two significant steps to reshape our portfolio through the sale of a controlling interest in HC2 Broadcasting and, shortly after quarter-end, the sale of DBM Global to IES. These transactions mark meaningful progress in our efforts to unlock the value of our assets, generate funds to help address coming debt repayment and redemption obligations, and further simplify INNOVATE's portfolio and capital structure.”

Avie Glazer, Chairman of INNOVATE

“Our focus now turns to the opportunities within our remaining portfolio, addressing liquidity and continuing to maximize value for INNOVATE shareholders. MediBeacon continues to build commercial momentum and advance its commercialization efforts in the U.S. and China, while HC2 Broadcasting is actively pursuing initiatives to unlock greater potential for its spectrum assets.”

Paul Voigt, Interim CEO of INNOVATE
4:22 PM ET 10-Q
Financial Results Sanara MedTech Inc. SMTI

Sanara MedTech Q3 2026 Results: Net Loss of $1.41M, Loss Narrows

Sanara MedTech reported net revenue of $84.4 million for the nine months ended September 30, 2026, a 12% increase over the prior year. Despite higher gross profits, the company recorded a net loss of $1.4 million for the period, primarily due to increased selling, general, and administrative expenses and interest costs.

Key figure
Net loss $1.41M
4:22 PM ET 8-K
Financial Results Lulu's Fashion Lounge Holdings, Inc. LVLU

Lulu's Fashion Lounge Holdings Financial Results

Lulu’s Fashion Lounge reported a 20% decline in Q3 2026 net revenue to $58.6 million, driven by lower order volumes and higher return rates. Despite the revenue headwind, the company achieved a 230-basis-point gross margin expansion and a 17% reduction in inventory as it continues an assortment reset strategy.

Term
Q3 2026

“During the third quarter, we continued to advance our assortment reset and saw encouraging signs from newer product, even as the impact of historical assortment decisions remained a headwind to customer engagement and repeat purchasing behavior. While these pressures continue to weigh on revenue, we are encouraged by the improving productivity and reorder eligibility of 2026 product introductions, which reinforces our confidence that refocusing the assortment on the categories and customers where Lulus has historically differentiated itself is the right path to rebuilding customer engagement over time.”

Crystal Landsem, CEO of Lulus

“Throughout the third quarter, we maintained a disciplined approach to inventory management, expense control and working capital as we continued to drive greater efficiency across the business.”

Heidi Crane, CFO of Lulus
4:22 PM ET 8-K
Financial Results Codexis, Inc. CDXS

Codexis Financial Results

Codexis reported Q3 2026 revenue of $19.3 million, a significant increase from $8.6 million in the prior year, driven by higher product revenue from new customer launches. The company also highlighted a new $60 million term loan facility with Trinity Capital and the successful scale-up of its ECO Synthesis Manufacturing Platform to 100-gram scale.

Term
Q3 2026

“I am pleased with our outstanding progress in 2026, through both innovation and technical achievements, that has garnered attention from leading innovators in the siRNA field.”

Alison Moore, PhD, President and Chief Executive Officer

“We have made significant progress in industrializing our technology while simultaneously increasing our revenue base, managing expenses, and improving the financial stability of our company.”

Alison Moore, PhD, President and Chief Executive Officer
4:21 PM ET 10-Q
Financial Results Decoy Therapeutics Inc. DCOY

Decoy Therapeutics Q3 2026 Results: Net Loss of $2.99M, Loss Widens

Decoy Therapeutics Inc. reported a net loss of $7.59 million for the nine months ended September 30, 2026, compared to a $3.54 million loss in the prior year period, driven by a significant increase in research and development expenses. The company recognized $535,059 in grant revenue during the period and maintains a cash balance of approximately $8.17 million as of September 30, 2026.

Key figure
Net loss $2.99M
4:21 PM ET 10-Q
Financial Results Immucell Corp ICCC

Immucell Q3 2026 Results: Turns Profitable, Net Income $953K

ImmuCell Corporation reported a settlement of $2.0 million with a former contract manufacturer and a $0.1 million regulatory fee reversal following the decision to cease focus on Re-Tain®. The company is currently refitting approximately $11.8 million in idle manufacturing assets for First Defense® production and reported anti-dilutive stock options totaling 968,978 for the quarter ended September 30, 2026.

Key figure
Net income $953K
4:21 PM ET 10-Q
Financial Results Volitionrx Ltd VNRX

Volitionrx Q3 2026 Results: Net Loss of $3.8M, Loss Narrows

VolitionRx reported total revenues of $3.0 million for the nine months ended September 30, 2026, a significant increase from $1.3 million in the prior year, primarily driven by product sales. Despite higher revenues, the company recorded a net loss of $17.8 million for the period, impacted by $15.9 million in operating expenses and $5.0 million in other expenses including debt extinguishment costs.

Key figure
Net loss $3.8M
4:21 PM ET 10-Q
Financial Results Soundthinking, Inc. SSTI

Soundthinking Q3 2026 Results: Net Loss of $8.47M, Loss Widens

SoundThinking reported a net loss of $20.2 million for the first nine months of 2026, a significant increase from the $6.6 million loss in the prior year period, driven by a decline in revenues and higher general and administrative expenses. The company also announced a pending acquisition by Transom Capital Group, LLC, which has introduced uncertainties regarding the transaction's completion and its impact on business operations.

Key figure
Net loss $8.47M
4:21 PM ET 10-Q
Financial Results Lineage Cell Therapeutics, Inc. LCTX

Lineage Cell Therapeutics Q3 2026 Results: Turns Profitable, Net Income $4.23M

For the nine months ended September 30, 2026, Lineage Cell Therapeutics reported total revenues of $4.2 million, a decrease from $7.9 million in the prior year, primarily due to lower collaboration revenues. The company significantly reduced its net loss compared to 2025, aided by a substantial $31.2 million non-cash gain from the change in fair value of warrant liabilities.

Key figure
Net income $4.23M
4:21 PM ET 10-Q
Financial Results Park Dental Partners, Inc. PARK

Park Dental Partners Q3 2026 Results: Net Income $1.7M, Up 36.1% YoY

For the nine months ended September 30, 2026, Park Dental Partners reported revenue of $193.8 million, a 5.8% increase year-over-year, though net income decreased to $2.7 million from $5.4 million due to higher salaries and share-based compensation. The company maintained a solid liquidity position with $23.2 million in cash and cash equivalents while continuing to expand through dental practice acquisitions.

Key figure
Net income $1.7M · +36.1% YoY

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.